Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2010
10/05/2010US7807620 Synthetic, for the enhancement of fertility, egg production and/or spermatogenesis
10/05/2010US7807618 Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone and other tissues
10/05/2010US7807617 Peptide inhibitors of toxins derived from LL-37
10/05/2010US7807463 Pretreatment of animal with antibodies to sensitize animal; controlling dosage
10/05/2010US7807458 Nutrient broth comprising multipotent cells for use in propagation of mesodermal, neuroectodermal, and endodermal cells; tissue engineering
10/05/2010US7807457 Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars
10/05/2010US7807441 Nucleotide sequences which code protein that induces cytotoxic T-lymphocyte immunity against weak selfproteins; antitumor agents
10/05/2010US7807430 Polypeptide of 250-419 contiguous amino acids of SEQ ID NO:1, where tyrosine 216 is phosphorylated and the polypeptide will crystallize; biological activity consisting of binding a GSK3 inhibitor and kinase activity; antidiabetic agents; Alzeimer's disease; antiinflammation agents; biological screening
10/05/2010US7807413 making modified human Interleukin-8 (IL-8) protein; inhibition of the interaction of chemokines and their high-affinity receptors on leukocytes and methods for the therapeutic treatment of inflammatory diseases; glycosaminoglycan-binding proteins (GAG)
10/05/2010US7807412 Using platelete derived growth fator as tool in detection of modulators for prevention and treatment of cell proliferative disorders
10/05/2010US7807397 Diagnostic method for disorders using copeptin
10/05/2010US7807396 Drug screening; Preventing amyloid plaque formation and/or growth by reacting amyloid peptides with peptidase via direction injection to the brain; gene expression; genetic engineering
10/05/2010US7807390 G-protein coupled receptor ligands and methods
10/05/2010US7807387 Biological agent that causes IL-6 receptor release
10/05/2010US7807384 Drug screening; identifying a candidate agent that inhibits the binding of low density lipoprotein binding protein-2 (LBP-2) to an LBP-2 binding molecule
10/05/2010US7807355 drug screening; identifying a therapeutic for decreasing intraocular pressure raised due to frizzled related protein (FRP) overexpression; contacting a trabecular meshwork cell expressing a Wnt pathway component or a frizzled related protein gene product with a test compound
10/05/2010US7807198 containing a polymer, a therapeutic agent, and a complexing agent, where the polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex; may be used to deliver a therapeutic agent in treatment of various disorders
10/05/2010US7807193 Method of treating insulin resistance, adult onset diabetes and metabolic syndrome X
10/05/2010US7807184 Heat resistant, chimeric verotoxin subunits for use in developing vaccine for prevention and treatment of microorganismal infection
10/05/2010US7807178 Muteins of placental growth factor type I, preparation method and application thereof
10/05/2010US7807177 Segment of glycosylation-deficient HGFalpha-chain
10/05/2010US7807176 Polypeptide promoting vascular endothelial cell growth
10/05/2010US7807175 Therapeutic vaccine
10/05/2010US7807173 Avian influenza; Hemagglutinin
10/05/2010US7807171 Conjugates comprising amino acid sequences derived from extracellular loop of P170 protein; each peptide having multiple fatty acid attachments and virosomes or liposomes; inducing anti P170 antibodies; synthesis
10/05/2010US7807170 Modulating an immune response in a subject by administering an effective amount of a lymphocyte differentiation factor; antiinflammatory agents
10/05/2010US7807167 using an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin; treatment of multiple sclerosis or inflammatory disease of the gastrointestinal tract
10/05/2010US7807166 Stimulating remyelination of central nervous system axons by administering a monoclonal antibody characterized by their ability to bind structures and cells within the central nervous system, including oligodendrocytes; including neural dysfunction caused by spinal cord injury
10/05/2010US7807164 Lyophilized VEGF antagonist formulations for intravitreal administration
10/05/2010US7807147 Tumor therapy with high affinity laminin receptor-targeted vectors
10/05/2010US7807145 Method of inducing neuronal production in the brain and spinal cord
10/05/2010US7807143 treating or delaying the onset of multiple sclerosis using enteric Alpha-melanocyte stimulating hormone (MSH); soluble immune response suppressor (SIRS)
10/05/2010US7807142 comprising interleukin-2 (IL-2); using an amino acid base sufficient to decrease aggregate formation of the polypeptide during storage of the composition, and a buffering agent ; mixture with amino acid and buffer
10/05/2010US7807134 BBN[7-13] peptide as targeting molecule, paclitaxel as therapeutic agent, a polyethylene glycol linker, a lysine or diamino benzoic acid core molecule, biotin as scaffold binding element and streptavidin as the scaffold moiety; anticarcinogenic agents; improved pharmacokinetics; intraveinous injection
10/05/2010US7807133 Diagnosis, therapy of tumors; as compared to avidin, the diavidins have shown ability to increase amount of labelled biotin on target, when used in an in vitro pretargeting test using supported human tenascin, the biotinylated anti-tenascin monoclonal antibody (Mab-B), avidin/diavidin, and biotin-3H
10/05/2010CA2444809C A non-lethal method for extracting crude hemocyanin from gastropod molluscs
10/05/2010CA2428662C Small acid-soluble spore protein and uses thereof
10/05/2010CA2391161C Pharmaceutical combinations comprising a p2t receptor antagonist and an anti-thrombotic agent
10/05/2010CA2369595C Conjugate having a cleavable linkage for use in a liposome
10/05/2010CA2233071C Use of growth hormone for recovering renal function
10/05/2010CA2157219C Process for purifying recombinant human serum albumin
10/05/2010CA2086325C Ligand for cd28 receptor on b cells and methods
09/2010
09/30/2010WO2010111702A1 Methods for preventing and treating angioedema
09/30/2010WO2010111669A1 Oncofetal antigen/immature laminin receptor peptides for the sensitization of dendritic cells for cancer therapy
09/30/2010WO2010111653A2 Modulating ires-mediated translation
09/30/2010WO2010111617A2 Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
09/30/2010WO2010111598A1 Methods for improving neurological outcome after neural injury and neurodegenerative disease
09/30/2010WO2010111597A2 Immunodominant compositions and methods of use therefor
09/30/2010WO2010111525A2 Treatment of carpal tunnel syndrome by injection of the flexor retinaculum
09/30/2010WO2010111516A2 Compositions and methods for inhibiting biofilms
09/30/2010WO2010111485A1 Compositions for stimulation of mammalian innate immune resistance to pathogens
09/30/2010WO2010111421A2 Isoform nell-1 peptide
09/30/2010WO2010111240A2 Methods for treating inflammatory arthritis
09/30/2010WO2010110931A2 Glycoconjugate vaccines
09/30/2010WO2010110908A2 Transdermal venous access locking solution
09/30/2010WO2010110503A1 INTERFERON-α (IFN-α) FUSED PROTEIN HAVING IFN-α AND CYTOPLASMIC TRANSDUCTION PEPTIDE (CTP)
09/30/2010WO2010110455A1 Polyion complex comprising hydrophobized polyamino acid and use of same
09/30/2010WO2010110439A1 Composition for regulating autonomic nervous activity and method for regulating autonomic nerve
09/30/2010WO2010109706A1 Therapeutic agent for cancer having reduced sensitivity to molecular targeted drug, and pharmaceutical composition for enhancing sensitivity to molecular targeted drug
09/30/2010WO2010109284A1 Antimicrobial cationic lipo-beta-peptides
09/30/2010WO2010109257A1 Composition to treat protein intolerance
09/30/2010WO2010109256A1 Enhanced treatment of joint and connective tissue damage
09/30/2010WO2010109168A2 Angiogenesis methods, medicaments and agents
09/30/2010WO2010109066A1 Dysfunction of the mitochondrial respiratory chain, methods for diagnosis, treatment and follow-up
09/30/2010WO2010109042A1 Composition for the prevention or treatment of diabetes mellitus
09/30/2010WO2010108942A1 Fertilization modulation compounds and process for implementing them
09/30/2010WO2010108665A1 Promotion of neuronal integration in neural stem cell grafts
09/30/2010WO2010108503A1 Promotion of neuronal integration in neural stem cell grafts
09/30/2010WO2010108262A1 TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC β-CELL DYSFUNCTION
09/30/2010WO2010108215A1 Compounds and methods for modulating an immune response
09/30/2010WO2010091373A3 Trimerich hiv fusion inhibitors for treating or preventing hiv infection
09/30/2010WO2010068714A3 Deuterated compounds as hepatitis c virus (hcv) inhibitors
09/30/2010WO2010065491A3 Methods of treating inflammatory disorders
09/30/2010WO2009120831A8 Novel n-and c-terminal substituted -antagonistic analogs of human gh-rh
09/30/2010WO2009120082A9 Means and methods for influencing electrical activity of cells
09/30/2010WO2009108554A3 System for delivery of protein in insoluble fibrillar or aggregate form
09/30/2010US20100249794 Composite Bone Graft Substitute Cement and Articles Produced Therefrom
09/30/2010US20100249747 Transdermal venous access locking solution
09/30/2010US20100249746 Drug delivery system for accelerated subcutaneous absorption
09/30/2010US20100249376 NELL Peptide Expression Systems and Bone Formation Activity of NELL Peptide
09/30/2010US20100249372 Botulinum neurotoxin a receptor and the use thereof
09/30/2010US20100249218 Method to inhibit cell growth using oligonucleotides
09/30/2010US20100249217 Modulators of pharmacological agents
09/30/2010US20100249216 Method for the production of a cell and/or tissue and/or disease phase specific medicament
09/30/2010US20100249045 Multimodal Abuse Resistant and Extended Release Opioid Formulations
09/30/2010US20100249044 Biogel
09/30/2010US20100249043 Compositions and methods for promoting hair growth
09/30/2010US20100249042 Compositions and methods for treatment of eyelashes and eyebrows
09/30/2010US20100249041 Compositions comprising ornithine ketoglutarate (okg)
09/30/2010US20100249040 Alpha-fetoprotein peptides and uses thereof
09/30/2010US20100249039 Methods for Treating Cancer Using an Immunotoxin
09/30/2010US20100249038 Antagonists of the receptor for advanced glycation end-products (rage)
09/30/2010US20100249037 Animal Model For Infant Pathologies
09/30/2010US20100249036 Method for treating depression
09/30/2010US20100249035 Peptides, compositions and uses thereof
09/30/2010US20100249034 Gfralpha3 and its uses
09/30/2010US20100249033 Polymer factor ix moiety conjugates
09/30/2010US20100249032 Human EPO Mimetic Hinge Core Mimetibodies, Compositions, Methods and Uses
09/30/2010US20100249031 Nutritional Composition Comprising Curcuminoids and Methods of Manufacture
09/30/2010US20100249030 Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
1 ... 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 ... 3163